Cyclic Mastalgia (Investigational Adjunct)
Investigational adjunct for severe cyclic mastalgia; first-line care includes proper-fit support, evening primrose oil (debated), and (for severe disease) tamoxifen or danazol short-course.
Patienten-Zusammenfassung
- Ist dies FDA-zugelassen fuer diese Anwendung?
- Not FDA-cleared for cyclic mastalgia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational with no controlled trials.
- Welche Evidenz existiert?
- Tier C (investigational). No controlled trials exist for hirudotherapy in cyclic mastalgia. Cyclic mastalgia is bilateral breast pain in the luteal phase, very common, usually self-limited, and most cases resolve with reassurance and a properly fitting bra. Evidence-based management for moderate-severe disease: trial of evening primrose oil (efficacy debated), reduction of caffeine and dietary fat, short-course luteal-phase tamoxifen 10 mg daily, or danazol for refractory severe disease (with significant androgenic side effects). Breast imaging is indicated to exclude underlying pathology in women over 30 or with focal findings.
- Hauptrisiken
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the chest wall for 5 to 10 days
- Local skin infection
- Allergic reaction to leech saliva
- Substantial bleeding and infection risk if a practitioner inappropriately places a leech on breast tissue or the nipple-areolar complex (this is not appropriate)
- Missed underlying pathology if mammography and ultrasound have not been performed in indicated patients
- Delay of bra fitting, lifestyle measures, and short-course tamoxifen, which are evidence-based
- Wer dies nicht in Betracht ziehen sollte
- Anyone offered direct breast or nipple-areolar placement (this is not appropriate)
- Pregnant or lactating patients
- Patients with breast implants in place at the proposed site
- Anyone with imaging not yet performed if age over 30 or focal mass
- Patients with suspected inflammatory breast cancer (urgent oncology referral)
- Patients with active mastitis or breast abscess
- Patients on anticoagulants or with severe anemia
- Was Sie Ihren Kliniker fragen sollten
- Has breast imaging excluded malignancy at my age and risk profile?
- Have I been properly bra-fitted by a trained fitter?
- Have I trialed evening primrose oil for at least 3 months, with reduced caffeine and dietary fat?
- Has short-course luteal-phase tamoxifen been considered for refractory severe disease?
- Where exactly will the leech be placed — confirm it is chest-wall skin lateral to breast tissue?
- What is the realistic expected benefit, given there are no controlled trials?
- Wann dringende medizinische Versorgung suchen
- A new lump or persistent focal area of pain or thickening
- Skin changes (peau d'orange, dimpling) or nipple discharge
- Spreading redness, warmth, swelling of the breast (rule out mastitis or inflammatory breast cancer)
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Hives, throat tightness, or breathing difficulty
Was dies NICHT bedeutet
- It is not applied directly to breast tissue or the nipple-areolar complex.
- It is not appropriate in pregnancy, lactation, or with breast implants.
- It does not substitute for proper bra fitting and imaging workup, both of which precede any pharmacologic or adjunct intervention.
- Only anecdotal evidence exists.
Sicherheits-Querverweise
Clinical Profile
- Category
- gynecologic
- ICD-10
- N64.4, N64.49
- Safety tier
- medium
Evidence Summary
Cyclic mastalgia is bilateral breast pain in the luteal phase, common, typically self-limited, and reassurance plus a properly fitting bra resolves most cases. Evidence-based management for moderate-severe disease: trial of evening primrose oil (efficacy debated), reduction of caffeine and dietary fat, short-course tamoxifen 10 mg daily during luteal phase, or danazol for refractory severe disease (significant androgenic side effects limit use). Breast imaging (mammogram, ultrasound) is indicated to exclude underlying pathology in women over 30 or with focal findings. No published controlled trials of hirudotherapy exist for cyclic mastalgia. Direct breast placement is anatomically high-risk and inappropriate; periphrastic chest-wall application is the only described approach.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Direct breast or nipple-areolar placement
- Pregnancy or lactation
- Breast implant (silicone or saline)
- Untreated breast pathology (cyst, mass, suspicious imaging)
- Inflammatory breast cancer suspected (urgent oncology referral)
Related Conditions
Lactational Mastitis (Non-Suppurative)
Investigational adjunctive use for non-suppurative lactational mastitis; case-series evidence for resolution of induration and reduced antibiotic days.
Endometriosis-Related Pelvic Pain
Investigational adjunctive use for chronic endometriosis-related pelvic pain; very limited evidence. Not a substitute for hormonal or surgical management.
Primary Dysmenorrhea
Investigational use for primary dysmenorrhea refractory to NSAIDs and hormonal contraception; small case series.
Chronic Pelvic Pain Syndrome (Non-Specific)
Investigational use for non-specific chronic pelvic pain syndrome; case-series evidence for symptom reduction within multimodal management.